LoCKAmp: lab-on-PCB technology for <3 minute virus genetic detection.

The recent COVID-19 outbreak highlighted the need for lab-on-chip diagnostic technology fit for real-life deployment in the field. Existing bottlenecks in multistep analytical microsystem integration and upscalable, standardized fabrication techniques delayed the large-scale deployment of lab-on-chip solutions during the outbreak, throughout a global diagnostic test shortage. This study presents a technology that has the potential to address these issues by redeploying and repurposing the ubiquitous printed circuit board (PCB) technology and manufacturing infrastructure.

Innovative Quantification of Critical Quality Attributes.

Potency testing is an important part of the evaluation of cellular therapy products. In vitro quantification of identified quality-related biomarkers is a technique often used at the laboratory. Nonetheless, the limited stability of most cellular therapy products, the lot variability and the limited time within which to perform testing are currently hindering their widespread use.

Printable graphene BioFETs for DNA quantification in Lab-on-PCB microsystems.

Lab-on-Chip is a technology that aims to transform the Point-of-Care (PoC) diagnostics field; nonetheless a commercial production compatible technology is yet to be established. Lab-on-Printed Circuit Board (Lab-on-PCB) is currently considered as a promising candidate technology for cost-aware but simultaneously high specification applications, requiring multi-component microsystem implementations, due to its inherent compatibility with electronics and the long-standing industrial manufacturing basis. In this work, we demonstrate the first electrolyte gated field-effect transistor (FET) DNA biosensor implemented on commercially fabricated PCB in a planar layout.

Ultra stable, inkjet-printed pseudo reference electrodes for lab-on-chip integrated electrochemical biosensors.

Lab-on-Chip technology comprises one of the most promising technologies enabling the widespread adoption of Point-of-Care testing in routine clinical practice. However, until now advances in Lab-on-Chip have not been translated to the anticipated degree to commercialized tools, with integrated device mass manufacturing cost still not at a competitive level for several key clinical applications. Lab-on-PCB is currently considered as a candidate technology addressing this issue, owing to its intuitive compatibility with electronics, seamless integration of electrochemical biosensors and the extensive experience regarding industrial manufacturing processes.